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SUMMARY
Dengue type 2 virus (DV)-induced cytotoxic factor (CF) is capable of reproducing various
pathological lesions in mice that are seen in human dengue. The present study was undertaken to
investigate the protective effect ofactive immunization ofmice with CF. Mice were immunized with 5
ug ofCF and prevention ofCF-induced increase in capillary permeability and damage to the blood-
brain barrier were studied at weekly intervals, up to 48 weeks, by challenging with 3 pg of CF.
Maximum protection against increase in capillary permeability and damage to the blood-brain
barrier was observed in week 4 after immunization. A breakthrough in the protection occurred with
higher doses of CF in a dose-dependent manner. Challenge with a lethal intracerebral (i.c.) dose of
DV showed significantly prolonged mean survival time and delayed onset ofsymptoms of sickness in
the immunized mice compared with the normal mice, but the titre ofthe virus in the brain was similar
in the two groups. On i.p. challenge with the virus the protection against damage to the blood-brain
barrier was 86 + 7% at week 4 and 17+4% at week 26 after immunization. Sera obtained from the
immunized mice showed the presence of CF-specific antibodies by ELISA, Western blot, and by
neutralization of the cytotoxic activity of CF in vitro. The present study describes successful
prevention of a cytokine-induced pathology by specific active immunization.
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INTRODUCTION
Cytokines act in a network of communication signals between
different types of cells. Under normal conditions the blood
concentration of cytokines is usually low, and they are quickly
eliminated or rendered inactive. Under pathological conditions
higher levels of different cytokines have been noted; however,
their role in the pathogenesis ofdisease is convincing for some of
them only. For example, the role of tumour necrosis factor
(TNF) in cerebral malaria [1-3], meningococcal septicaemia [4]
and lethal infection of Escherichia coli in baboons [5] is known.
Other cytokines which may produce pathological effects are IL-
1 [6], IL-6 [7], IL-8 [8] and others [9].
Dengue haemorrhagic fever/shock syndrome (DHF/DSS) is
characterized by increased vascular permeability, thrombocyto-
penia, alterations in blood leucocytes and cerebral oedema. The
pathogenesis of the disease is not known, nor is an effective
vaccine available (reviewed in [10]). During dengue type 2 virus
(DV) infection of mice a cytokine, called cytotoxic factor (CF),
is produced by T cells of the spleen. CF is a highly potent protein
molecule of 43-45 kD with an isoelectric point of pH 6 5. A
sequence of 19 amino acids of the N-terminus ofCF differ from
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that of other known cytokines and the dengue virus-specific
proteins (Gen Data Base, compared at Distributed Information
Centre, Indian Institute of Science, Bangalore), thus indicating
that it is a unique cytokine. Oligonucleotide probes derived from
this sequence show the presence ofmRNA for CF in the spleen
cells of DV-infected mice ([1 1]; unpublished data). CF killed
mainly H-2A-negative macrophages, T helper (Th) cells and
megakaryocytes of lymphoid cells from a variety of animal
species, including mice, by increasing influx ofCa2+ in them. CF
induces H-2A-positive macrophages to produce another cyto-
toxin (CF2). CF/CF2 are capable of producing a number of
pathological lesions in mice, which include reversible increase in
vascular permeability and damage to the blood-brain barrier
due to release of histamine. In vitro treatment of human blood
leucocytes with CF decreases the E-rosetting capacity ofT cells
and the functions ofmonocytes, which are similar to the changes
described in cases of DHF/DSS [12]. It would thus appear that
CF is capable ofreproducing the pathological lesions ofDHF in
mice [13-20]. The concept of pathogenesis-related proteins
during viral infection of plants is well established [21]. It appears
that CF is a pathogenesis-related protein, at least in mouse
dengue infection.
Efforts have been made to neutralize the adverse effects of
the cytokines by passive immunization, for example by adminis-
tration of antibodies against TNF [1]. The pathological effects
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produced by CF/CF2 could be prevented by passive administra-
tion of the specific antibody in mice [16,17,19]. In the present
study, an effort was made to investigate whether a vaccine could
be developed for dengue using CF as antigen. We describe here
our limited success in this regard.
MATERIALS AND METHODS
Mice
The study was carried out on inbred Swiss albino mice aged 2-3
months, obtained from the colony maintained in this Depart-
ment.
Virus
DV, strain P 23085, obtained from the National Institute of
Virology, Pune, India, was used in the form of infected mouse
brain suspension. The titre of the virus was estimated in the
brain tissue of mice following intracerebral (i.c.) inoculation of
DV as described [16,22]. Briefly, serial 10-fold dilutions of the
brain suspension were inoculated intracerebrally in groups ofsix
mice each and the mortality was recorded. The virus titre was
calculated by the method of Reed & Muench [23] and expressed
as logl0 LD50 for 30 pI of the brain suspension. Normal mouse
brain homogenate (NMB) was used as control in some experi-
ments.
Preparation of the cytotoxic factor
CF was prepared from DV-infected moribund mouse spleen
cells as described elsewhere [11] and its cytotoxic activity was
assayed [24]. CF was purified with a Pharmacia low pressure
liquid chromatography (LPLC) system using Sephacryl S-200
gel column, and was dried in a Speed Vac (Savant Instrument
Company, New York, NY). The amount of protein was
estimated by the technique ofLowry et al. [25]. The purity ofCF
was established by SDS-PAGE. Normal mouse spleen cell
culture supernatant (NF) was similarly prepared and used as a
control.
Immunization ofmice
Mice were immunized with 5 pg of purified CF protein
emulsified in Freund's incomplete adjuvant (FIA; Sigma
Chemical Co., St Louis, MO) subcutaneously on the dorsal
aspect. The control mice were similarly given NF. At different
intervals blood was collected from the eyes of mice, sera were
separated and stored at -20'C.
Assay of blood-brain barrier permeability
The leakage of plasma proteins into the brain substance was
measured by assay ofplasma protein-bound Evans blue dye into
the brain [16]. Briefly, mice were inoculated intravenously with
200 pl of a 2% solution of Evans blue dye dissolved in PBS pH
7-2. After I h the mice were anaesthetized with halothene
intraperitoneally and the brain was perfused with 5 ml PBS via
the left heart ventricle. Whole brain was removed and a 10%
(w/v) homogenate was prepared in PBS and centrifuged at 40C
at 6000 g for 15 min. The clear supernatant was screened for
absorbance at 590 nm for the detection of protein-bound dye.
The protein contents in the brain supernatant were calculated
from the standard curve of bovine serum albumin (BSA) and
expressed as pg protein/ml [19]. The results were expressed as
permeability index (PI) of the blood-brain barrier [16], calcul-
ated as follows:
PI =
100 x (protein in DV-inoculated mice -background value)
(protein in NMB-inoculated control mice -background value)
-100
Following challenge with CF the PI in immunized mice was
compared with PI in normal control mice and expressed as per
cent protection calculated as follows:
Per cent protection=
(PI in immunized mice - PI in control mice)
PI in control mice x 100
Assay of capillary permeability
Measurement of leakage of plasma protein-bound Evans blue
dye from the vascular compartment into the peritoneal cavity of
the mouse was used to estimate the integrity of the capillary
permeability, as described previously [17]. Briefly, mice were
inoculated intravenously with 100 p1 of Evans blue dye solution,
followed 5 min later with CF intraperitoneally. After 30 min
mice were anaesthetized and the peritoneal cavity was washed
with 5 ml PBS. The lavage fluid was collected, filtered through
glasswool column and made up to final volume of 10 ml. The
optical density at 590 nm was determined with a spectrophoto-
meter. The protein content of the fluid was calculated as pg
protein/ml. The results were expressed as PI, as described above.
The control mice were inoculated with NF. The per cent
protection in immunized mice was calculated as described
above.
ELISA
The technique of Voller et al. [26] was used with some
modifications to set up ELISA. Briefly, 100 pi containing 3 ng of
purified CF in PBS were added to the flat-bottomed ELISA
plates (Titertek Immuno Assay Plates 77-173-05; Flow Labs,
Zwanenburg, The Netherlands), and incubated overnight in a
moist incubator at 370C. The plate was washed three times with
PBS containing 0 05% Tween 20 (PBS-T) and blocked with
blocking buffer containing 1% milk protein (Lactogen-l milk
powder, Nestle India Ltd., New Delhi, India) in PBS for 1 h. The
plate was washed again three times with PBS-T, and 100 p1 of
1:200 diluted serum from immunized or normal mice were
added and the plate was incubated at 370C for 1 h. After
washing the plate, 100 pi of protein A conjugated with
horseradish peroxidase (HRP; a gift from the National Institute
of Immunology, New Delhi, India) diluted 1: 10 000 in dilution
buffer (blocking buffer plus 0-5% Tween 20) were added and
were incubated at 370C for 1 h. The plate was washed and 100 p1
of the mixture of o-phenylenediamine and H202 in citrate buffer
(0 02 M) pH 5.0 were added and incubated at room temperature
for about 10 min. The reaction was stopped with 50 p1 of 2 5 N
H2SO4 and the absorbance was read at 492 nm. Each serum
sample was tested in duplicate and the mean absorbance in wells
without CF was subtracted from the mean absorbance in wells
with CF before analysis. The cut-offvalue for seropositivity was
determined by adding 2 x s.d. to the mean absorbance ofnormal
mouse serum controls.
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Fig. 1. Protection against cytotoxic factor (CF)-induced increase in
vascular permeability of mice by specific active immunization. Groups
of normal control and immunized mice at different periods were
challenged with 3 jg ofCF and the vascular permeability was assayed.
The per cent protection was calculated as described in Materials and
Methods. Each point represents mean value+ s.d. from 10 to 12 mice.
Assay ofneutralization of the cytotoxicity ofCF in vitro by sera
of immunized mice
Sera obtained at different periods after immunization were
doubly diluted and mixed with equal volume of CF and
incubated at 370C for I h. The target cells (2 x 106 normal mouse
spleen cells) were then added to the mixture and incubated at
40C for 1 h. Non-viable cells were then counted using the trypan
blue dye exclusion method [24]. The control mice were similarly
treated with normal mouse sera. Per cent neutralization of the
cytotoxicity by immunized mice sera was calculated.
Plan ofstudy
Mice immunized with CF were investigated at different periods
from I to 48 weeks for their (i) capacity to withstand the
challenge with CF itself or DV; (ii) presence of CF-specific
antibodies; and (iii) the capacity of their sera to neutralize the
cytotoxicity of CF on the target cells in vitro. The parameters
used to measure the resistance to challenge with CF or DV were
inhibition of the damage to (i) the blood-brain barrier and (ii)
the vascular permeability in immunized mice compared with
normal control mice. The data are presented as mean
value+ s.d. from 10 to 12 mice in each group. Student's t-test
was used to analyse the data, and P< 005 was considered
significant.
RESULTS
Effect of challenge of immunized mice with CF
CF-immunized mice were challenged with 3 pg ofpurified CF to
assay the protective effect at different periods after immuniza-
tion.
Effect on vascular permeability. The indicator of protective
response was per cent decrease in CF-induced increase in
capillary permeability in immunized mice compared with the
normal control mice challenged with 3 pg of CF. The data
summarized in Fig. 1 show that the extent of protection against
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Fig. 2. Dose-dependent protection against cytotoxic factor (CF)-
induced increase in vascular permeability of mice by specific active
immunization. Groups of mice at week 4 of immunization and normal
mice were challenged with various doses of CF and the vascular
permeability was assayed and per cent protection calculated. Each point
represents mean value+s.d. from 10 to 12 mice.
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Fig. 3. Cumulative mortality of mice injected with 100 LD50 of dengue
type 2 virus (DV) intracerebrally (0), normal mice; 0, at week 3; *, at
week 4; *, at week 6; A, at week 20 after immunization. Each group
consisted of 10 mice.
challenge with CF quickly increased with time after immuniza-
tion, being 20 + 2% at week I to the peak of almost complete
protection (96 + 3%) at week 4. The capacity to protect declined
gradually up to week 14, when the protection varied between
65% and 80%. The protection was 21-39% during week 16 to
week 48 after immunization.
Dose response ofCF challenge. In another set of experiments
the dose response of the CF challenge was investigated. For this,
mice with peak protective response at week 4 after immuniza-
tion were chosen. Groups of immunized and control normal
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which at weeks 4 and 26 after immunization were challenged
with 3 yg of CF intravenously, and the permeability of the
blood-brain barrier was assayed. It was observed that the
protection at week 4 was 52 + 6%, while that at week 26 was
13+4%.
Effect of challenge of immunized mice with DV
3_ The immunized and normal control mice were inoculated
intracerebrally with 1000 LDs; of DV, and various observations
2- were made.
Sickness and mortality ratio. Following i.c. inoculation of
I 2;/ normal mice with DV, the mice appeared healthy up to day 5 p.i.
On day 6 p.i. arching of the back and ruffling of the fur occurred,
0 I I I which was followed by severe sickness with paralysis of limbs on
2 3 4 5 6 7 8 9 days 8 and 9. All the mice died by day 11 p.i. The mean survival
Time post-infection (days) time was 10+ 0-8 days. In contrast, the mice at 3, 4 and 6 weeks
4. Virus titres in the brain tissue of mice on different days after after immunization remained apparently healthy up to day 11
tion with 1000 LD50 of dengue type 2 virus (DV) intracerebrally p.i., and no ruffling of fur or arching of back occurred. On days
normal mice; 0, at week 4; 0, at week 10 after immunization. Each 12 or 13 they developed paralysis and died within the next 24 h.
t represents mean value+ s.d. from three mice. The mice at week 20 after immunization behaved like normal
mice. The findings presented in Fig. 3 show the cumulative
mortality rate in control and immunized mice. The curve has
shifted significantly (P < 0-001) to the right with mice at 3, 4 and
*0- 6 weeks after immunization. The cumulative mortality ratio of
mice at week 20 of immunization was similar to that of normal
.9- control mice.
_
Virus titre in the brain of mice. The immunized and normal
. mice were inoculated with 1000 LD50 of DV. From each group
.7
-
three mice were killed 2, 4, 6 and 8 days p.i. and the brains were
_ ; * assayed for the virus titre. The data summarized in Fig. 4 show
. . that the virus titres in the brains of immunized mice were similar
.5 - . . to those of normal control mice.
* * . Effect on the blood-brain barrier. Groups of mice at weeks 4
l £ - *. _ * and 26 after immunization and the normal control mice were
.3- . * * challenged with 1000 LD50 ofDV intracerebrally or intraperito-
,,------t ---.-{->-rX--------- neally. The data obtained show that at week 4 after immuniza-
2 . 0:0 :* X tion protection to DV i.c. challenge with DV was 53 +4%, and
I A~~~£ i>.Ie J * that to i.p. challenge was 86 + 7%. At week 26 after immuniza-
* tion it was 11±+2% and 17 +4%, respectively.
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Fig. 5. Scatter diagram ofELISA seroactivity to cytotoxic factor (CF) in
sera from normal healthy control mice and at different periods after
active immunization with CF. Each point represents mean value of
duplicate test on one serum sample. The horizontal bars indicate the
mean absorbance for each group, and the dashed line the cut-off value
for seropositivity. All points above the dashed line were considered
seropositive.
mice were challenged with various doses ofCF, and the per cent
protection was calculated. The findings shown in Fig. 2 indicate
that the capacity of immunized mice to resist the CF-induced
increase in capillary permeability declined in a dose-dependent
manner, being 96+3% with 3 Mg ofCF and 19 +4% with 30 pg
of CF.
Effect on blood-brain barrier. The effect of CF challenge on
the blood-brain barrier was examined in a few groups of mice
Presence of anti-CF antibodies in immunized mice
Groups of mice immunized with CF were bled and the serum
from individual mice was investigated for the presence of anti-
CF antibodies at different periods.
ELISA test. At 1 week after immunization 56% of sera had
anti-CF antibody titres above the cut-off value in the ELISA.
The seropositivity was 100% during the weeks 2-8, and then
declined gradually to 21% at week 24. At later periods none of
the sera was positive (Fig. 5). The mean antibody titres
gradually increased during the post-immunization period,
reaching peak values at week 4 and then declining. This
correlated with the extent of protection shown in Fig. 1.
Neutralization of the activity ofCF by sera of the immunized
mice. CF kills normal mouse spleen cells in vitro in 1 h at 4 C
[24]. The protective effect of the sera from immunized mice on
the cytotoxicity ofCF was therefore investigated. The ability of
the sera from immunized mice to neutralize the cytotoxicity of
CF gradually increased with the time after immunization till
week 4, persisted up to week 8, and then declined.
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DISCUSSION
The significant finding of the present study is that active
immunization by a cytokine (CF) protects mice against its
adverse effects on subsequent challenge. The protection against
the CF-induced increase in capillary permeability was complete
at week 4 after immunization to a challenging dose of 3 yg/
mouse of CF. A breakthrough in the protection occurred with
higher doses of CF in a dose-dependent manner. The sera
obtained from these mice had CF-specific antibodies as shown
by ELISA and Western blot tests (results not shown), and had
the capacity to neutralize the cytotoxic activity of CF in vitro.
All these effects were dependent on the period after immuniza-
tion.
On i.c. inoculation, DV replicates in the brain of mice, and
produces encephalitis followed by paralysis of limbs and death.
The virus spreads all over the body and can be detected in
different organs [27,28]. DV lacks the ability to invade the
central nervous sysetm (CNS) when inoculated by peripheral
routes (reviewed in [29]). Further, no apparent illness is
produced by i.p. inoculation ofDV in mice, but damage to the
blood-brain barrier and increase in vascular permeability,
mediated by CF, do occur [16,17]. The onset of paralysis was
delayed, mean survival time was significantly prolonged
(P <0001) and the clinical symptoms, like arching of the back
and ruffling of the fur, were mostly absent in CF-immunized
mice compared with the normal mice by lethal i.c. challenge with
DV. The virus titres in the brain tissue were similar in the two
groups. Similar prolonged mean survival times after a lethal
challenge with viruses have been reported in T cell-deficient
mice, such as athymic nude (nu/nu) mice [27] or those treated
with anti-thymocyte serum [30]. In DV-infected mice the brain is
damaged by replication of the virus and by a DV-induced T cell
cytokine, the CF [16]. It has been shown that paralysis and death
ofmice occur due to replication ofDV in the neuron cells, while
damage to the blood-brain barrier, resulting in cerebral oedema
and associated symptoms, is caused both by the virus and CF
[16,29]. In the present study neither the virus titre nor the DV-
induced paralysis and death could be prevented by CF immun-
ization, but the latter was significantly delayed and the path-
ological lesions produced by challenging the mice with CF were
prevented. On the other hand, in further experiments where the
virus did not enter the brain (i.p. inoculation) the immunization
provided specific protection (86 + 7%) against damage to the
blood-brain barrier on challenging with DV.
Several successful attempts have been made to immunize
passively animals with anti-cytokine antibodies to neutralize its
adverse effects. Beutler et al. [31] protected mice from the lethal
effects of endotoxin by passive immunization against TNF.
Development of cerebral oedema, haemorrhage and leakage of
protein across the blood-brain barrier in cerebral malaria are
prevented by antibodies against TNF, and a MoAb to E. coli [6].
Specific antisera protect mice against CF/CF2-induced increase
in capillary permeability and breakdown of the blood-brain
barrier [16-19].
However, it may noted that not all antibodies against
cytokines inhibit their function. Bendtzen et al. [32] have
reviewed the role of autoantibodies to cytokines, and have
suggested that anti-cytokine antibodies (neutralizing type) may
produce 'cytokine deficiency', thus inhibiting their functions,
while in some cases they (non-neutralizing type) contribute to a
positive therapeutic response by better targeting to the appro-
priate cells.
This initial success with active immunization using a cyto-
kine has raised several questions: (i) what is the minimum dose
ofCF required?; (ii) how many booster doses are needed, and at
what time?; (iii) what is the appropriate adjuvant for it?; and (iv)
what are the side effects, if any? Studies are in progress in this
direction.
Playfair et al. [3] have discussed the role of 'anti-parasite'
versus 'anti-disease' vaccine in relation to malaria. They have
cited evidence to show that soluble antigens (toxins) released
from Plasmodium falciparum have properties of bacterial lipo-
polysaccharides and induce over-production of TNF which is
responsible for the disease. Therefore, they have proposed the
possibility of an 'anti-toxic vaccine' that prevents the serious
pathological complications of the disease [3]. CF is a unique
cytokine induced by DV which is responsible for the production
of most of the pathological lesions which could be prevented by
passive immunization [16,17,20], and also by active immuniza-
tion as shown in the present study. Therefore, vaccine strategies
directed at the cytokine (the primary cause) rather than the
infective agents need serious consideration, especially when
effective vaccines are not available for several agents.
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